BPG is committed to discovery and dissemination of knowledge
Clinical Trials Study
Copyright: ©Author(s) 2026.
World J Diabetes. Jul 15, 2026; 17(7): 119604
Published online Jul 15, 2026. doi: 10.4239/wjd.119604
Table 2 Cluster-specific dysglycemia transitions and intervention effects: Adjusted hazard ratios and cumulative incidence
Variable
n
Events
Unadjusted 2-year CIF (%)
Adjusted 2-year CIF (%)1
95%CI (adjusted CIF)
aHR2
95%CI3 (aHR)
P value
Progression to diabetes
MARD104355.87.284.27-11.10Reference
MOD99175.13.381.70-5.950.520.29-0.930.028a
SID115287.05.202.66-8.490.840.51-1.390.496
SIR49194.18.324.69-12.840.880.50-1.570.673
Intervention (yes vs no)0.520.30-0.890.017a
Sex (male vs female)1.240.82-1.850.305
Regression to normoglycemia
MARD104111.93.031.41-5.17Reference
MOD99217.16.493.58-10.482.081.00-4.330.049a
SID115195.24.972.38-8.281.820.87-3.840.113
SIR4996.15.412.09-10.341.510.63-3.660.358
Intervention (yes vs no)0.630.33-1.200.159
Sex (male vs female)0.940.56-1.590.829
Persistence of prediabetes
MARD1045814.415.4910.99-20.46Reference
MOD996114.117.5012.53-22.741.180.82-1.690.380
SID1156822.617.2112.40-22.551.250.88-1.770.222
SIR49218.211.026.48-16.280.670.41-1.110.120
Intervention (yes vs no)0.570.40-0.810.002a
Sex (male vs female)0.900.68-1.190.459


Write to the Help Desk